About Kissei Pharmaceutical
Kissei Pharmaceutical is a publicly listed company based in Matsumoto (Japan) founded in 1946. Therapies for renal diseases and urology-related anemia are developed. The company has 1,780 employees. Its website kissei.co.jp draws about 113 thousand monthly visits. Its focus areas include Life Sciences, Immunotherapy, Vaccine and Therapeutic.
Company details
Kissei Pharmaceutical was founded in 1946 in Matsumoto, Japan, and operates within the pharmaceutical sector. Focus is placed on developing treatments for renal diseases and anemia associated with urology conditions. The lead product, JR-131, an injectable form of re-engineered erythropoietin, has completed phase III clinical trials for anemia management. Operations emphasize research and clinical advancement in these therapeutic areas.
- Headquarters Matsumoto, Japan
- Employees 1,780
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website kissei.co.jp
- Legal Name Kissei Pharmaceutical Co., Ltd.
- Annual Revenue$610.73 M (USD)10.28as on Mar 31, 2026
- Net Profit$86.4 M (USD)15.2as on Mar 31, 2026
- EBITDA$10.78 M (USD)-83.75as on Mar 31, 2026
- Employee Count1,780
People of Kissei Pharmaceutical
1 people are tracked at Kissei Pharmaceutical (1 in leadership); the tracked headcount is 1,780.
| Name | Role | Group |
|---|---|---|
Mutsuo Kanzawa | Chairman and CEO | Leadership |
Complete people profiles for Kissei Pharmaceutical
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Kissei Pharmaceutical
Kissei Pharmaceutical is a publicly listed company on the TSE with ticker symbol 4547 in Japan, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date22 Dec 1988
- Listed onTSE: 4547
- Listed entityKissei Pharmaceutical Co., Ltd.
- Exchange sectorHealth technology
- ISINJP3240600001
- Share price3,760.00 JPY (-0.92% on the day) · 2026-10-14
- Market capitalisation155,013,221,798.00 JPY
- Price to earnings11.1
- EPS (diluted, trailing year)337.33 JPY
- Dividend yield5.4%
- Volume (last session)78,700
Financials of Kissei Pharmaceutical
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 97.41B JPY | 13.78B JPY | 1.72B JPY |
| 2024 | 88.33B JPY | 11.96B JPY | 10.57B JPY |
| 2023 | 75.58B JPY | 11.16B JPY | 8.27B JPY |
| 2022 | 67.49B JPY | 10.53B JPY | 2.97B JPY |
| 2021 | 65.38B JPY | 12.92B JPY | 2.33B JPY |
Detailed financial statements for Kissei Pharmaceutical
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Web traffic of Kissei Pharmaceutical
The website of Kissei Pharmaceutical (kissei.co.jp) receives about 112.7K visits a month and ranks #264,372 among all websites worldwide, #8,984 in Biotechnology and Pharmaceuticals.
- Monthly visits112.7K
▼ 29.4% vs previous month
- Unique visitors93.5K
per month
- Global rank#264,372
among all websites
- Category rank#8,984
Health · Biotechnology and Pharmaceuticals
- Bounce rate63%
- Pages per visit2.0
- Average visit30 sec
- DevicesDesktop 40% · Mobile 60%
Websites whose visitors overlap most with Kissei Pharmaceutical. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
career.medpeer.jp | career.medpeer.jp | 100% | #165,285 | – | |
medpass.jp | medpass.jp | 99% | #339,717 | – | |
plamed.com | plamed.com | 99% | #179,526 | – | |
medicalcommunity.jp | medicalcommunity.jp | 97% | #251,238 | – | |
otsuka.co.jp | otsuka.co.jp | 94% | #76,610 | – | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 40 similar websites and full traffic analytics for Kissei Pharmaceutical
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 40 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Kissei Pharmaceutical
Complete news archive for Kissei Pharmaceutical
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Kissei Pharmaceutical
Kissei Pharmaceutical was founded in 1946.
Kissei Pharmaceutical is headquartered in Matsumoto, Japan. It is registered at Matsumoto, Nagano, Japan.
Kissei Pharmaceutical has 1,780 employees.
Annual revenue of Kissei Pharmaceutical is $610.73M as on Mar 31, 2026.
Kissei Pharmaceutical was founded in 1946 in Matsumoto, Japan, and operates within the pharmaceutical sector. Focus is placed on developing treatments for renal diseases and anemia associated with urology conditions. The lead product, JR-131, an injectable form of re-engineered erythropoietin, has completed phase III clinical trials for anemia management. Operations emphasize research and clinical advancement in these therapeutic areas.
Yes, Kissei Pharmaceutical is publicly traded on TSE under the ticker symbol 4547.
The website of Kissei Pharmaceutical receives about 113 thousand visits a month and ranks #264,372 among all websites worldwide.